Related Experiment Video
Updated: Dec 1, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Practical considerations when treating chronic hepatitis E in solid organ transplant recipients
David K Choi1, Michelle T Martin2, Wadih Chacra3
1University of Illinois at Chicago College of Pharmacy, 833 S Wood Street, Suite 164, M/C 886, Chicago, IL, 60612, USA. Dchoi90@uic.edu.
Abstract:
Hepatitis E virus (HEV) can lead to chronic infections in immunosuppressed patients. The use of ribavirin to treat chronic HEV has been well-established in case reports and guidelines. However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking. Thus, we present our real-world approach to the use of ribavirin to treat chronic HEV in a solid organ transplant recipient.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

